| DIRECT COMPETITOR COMPARISON | |
| NUTR | NTY | WNI | Pvt1 | Industry | | Market Cap: | 126.22M | 2.67B | 169.51M | N/A | 94.74M | | Employees: | 700 | N/A | 465 | N/A | 280 | | Qtrly Rev Growth (yoy): | -2.60% | 12.10% | 1.60% | N/A | 9.60% | | Revenue (ttm): | 161.89M | 2.58B | 191.47M | N/A | 71.35M | | Gross Margin (ttm): | 53.13% | 43.51% | 35.58% | N/A | 52.09% | | EBITDA (ttm): | 28.90M | 349.37M | 20.20M | N/A | 220.78K | | Oper Margins (ttm): | 13.80% | 10.86% | 8.98% | N/A | 8.30% | | Net Income (ttm): | -15.70M | 145.73M | 11.47M | N/A | N/A | | EPS (ttm): | -1.445 | 2.305 | 0.400 | N/A | N/A | | P/E (ttm): | N/A | 18.75 | 15.29 | N/A | 17.01 | | PEG (5 yr expected): | N/A | 0.87 | N/A | N/A | 0.98 | | P/S (ttm): | 0.78 | 1.03 | 0.89 | N/A | 1.20 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.40 | 0.97% | 58.10B | 12.52 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.29 | 0.23% | 13.97B | 16.16 | | Genzyme Corp. | GENZ | 50.30 | 0.64% | 13.35B | 28.68 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.77 | 0.39% | 42.09B | 18.09 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.62 | -0.04% | 9.03B | 1033.06 | | Teva Pharmaceutical Industries Limited | TEVA | 53.76 | -0.46% | 47.36B | 49.19 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 38.15 | 0.66% | 4.05B | 19.66 | | King Pharmaceuticals Inc. | KG | 11.64 | -0.68% | 2.89B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.2315 | 1.34% | 5.57B | 111.85 | | Pfizer Inc. | PFE | 18.4785 | -0.06% | 149.11B | 15.35 | | Johnson & Johnson | JNJ | 64.6539 | 0.46% | 178.39B | 14.12 | | GlaxoSmithKline plc | GSK | 42.6001 | -0.35% | 107.99B | 13.44 | | Sanofi-Aventis | SNY | 38.86 | -1.32% | 101.47B | N/A | | Novartis AG | NVS | 55.69 | 0.25% | 126.48B | 16.67 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.43 | 0.02% | N/A | N/A | | AstraZeneca plc | AZN | 46.365 | 0.14% | 67.23B | 9.31 | | Abbott Laboratories | ABT | 54.12 | 0.63% | 83.71B | 14.66 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 2.03% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | NTY | | NBTY To Webcast Presentation; Wedbush Securities California Dreamin' Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009
Mon 7:00am -
PR Newswire | | • | NTY | | NBTY INC Financials
Fri, Dec 4 -
EDGAR Online Financials | | • | NTY | | 4-Star Stocks on the Upswing
Thu, Dec 3 -
at Motley Fool | | • | NTY | | NBTY Senior Vice President Adopts Rule 10b5-1 Trading Plan
Wed, Dec 2 -
PR Newswire | | • | NTY | | NBTY INC Files SEC form 10-K, Annual Report
Mon, Nov 30 -
EDGAR Online | | • | WNI | | CEO Interview: GeoPharma, Inc. - Mihir K. Taneja
Mon, Nov 2 -
Wall Street Transcript | | • | WNI | | SCHIFF NUTRITION INTERNATIONAL, INC. Financials
Wed, Oct 14 -
EDGAR Online Financials | | • | WNI | | SCHIFF NUTRITION INTERNATIONAL, INC. Files SEC form 10-Q, Quarterly Report
Thu, Oct 8 -
EDGAR Online | | • | WNI | | New Star Analyst Rankings for SCHIFF NUTRIT INTL
Sat, Sep 19 -
StarMine | | • | WNI | | Schiff Nutrition International, Inc. Earnings Call scheduled for 11:00 am ET today
Thu, Sep 17 -
CCBN | | | All Headlines for these symbols... |
|
|
|
0.43% Nasdaq 
Competitors
